Atorvastatin also resulted in a 35 % greater reduction in CD8-T-cell activation than placebo ( 49 % vs. 14 % , P = 0.0009 ) , CD4 T-cell exhaustion ( 27 % vs. 17 % in placebo ) , P = 0.001 and CD8 T-cell exhaustion ( 27 % vs. 16 % ) , P = 0.004 .